The goal of the Human Biology Division is to cultivate interdisciplinary research focused on human biology and to increase the ongoing research on solid tumor cancer and other complex human diseases.
The Human Biology Division was formed in 1998 by merging Fred Hutch’s Cancer Biology Program and the Division of Molecular Medicine with an initiative in genetics/genomics. It is structured to foster and support ongoing laboratory-based and computational research at the interface of basic, clinical, and population sciences. The Division has more than 23 faculty members with expertise in molecular and cell biology, genomics, genetics, virology, infectious disease, computational biology, pathology and clinical research.
Division researchers are using a multidisciplinary approach to achieve a better understanding, diagnosis, treatment, and prevention of human disease. The research blends fundamental, applied, and translational research that is solidly grounded in high-quality basic research into molecular mechanisms, often performed in model organisms and in vitro systems.
The close interaction of this broad collection of talented and motivated investigators provides unique opportunities for synergistic collaborations. In other institutions, such a diverse faculty would be distributed among many different departments.
Expanding solid tumor translational research
The association of Fred Hutch with Seattle Cancer Care Alliance (SCCA) and University of Washington Medicine has tremendously expanded the care of patients with solid tumors. Fred Hutch, world renowned for its research and treatment of hematologic malignancies, has committed to increasing the ongoing research on solid tumor cancer biology that is being done in the Human Biology and Clinical Research divisions, as well as the excellent population-based research on solid tumors done in the Public Health Sciences Division.
The goal is to translate this focused commitment to effect future advances in solid tumor treatment. Human Biology researchers specializing in solid tumors are part of the Seattle Translational Tumor Research (STTR) group, which was formed to solidify Fred Hutch’s commitment to solid tumor research. Its goal is to enhance the understanding of cancer biology and therapeutic responses and to identify personalized treatments that improve patient outcomes.
The STTR bridges together physicians and scientists from Fred Hutch, UW Medicine and SCCA focusing on laboratory sciences and patient care to provide the most precise treatment options for patients with solid tumor cancers. Collectively, these leading cancer research and clinical care organizations are enhancing our knowledge of cancer using population research, preclinical cancer biology, translational, imaging and clinical studies of solid tumors.
The Division's laboratories occupy all three floors of the Hutchinson Building at 1100 Fairview Ave. North, and parts of the adjacent Thomas Building on the Robert W. Day Campus at South Lake Union.
Skybridges connect the HB labs with other division at Fred Hutch, allowing scientists to move easily between buildings and collaborations to happen naturally. In addition, graduate students and postdoctoral fellows have the opportunity to share mentors across the five scientific divisions through our interdisciplinary training grants, providing an important link among faculty.
Fred Hutch is proud to be an Equal Opportunity and VEVRAA Employer. We are committed to cultivating a workplace in which diverse perspectives and experiences are welcomed and respected. We do not discriminate on the basis of race, color, religion, creed, ancestry, national origin, sex, age, disability, marital or veteran status, sexual orientation, gender identity, political ideology, or membership in any other legally protected class. We are an Affirmative Action employer. We encourage individuals with diverse backgrounds to apply and desire priority referrals of protected veterans. Read the EEO is the Law poster here.